Chapter 1. Research Background
1.1. Research Objectives
1.2. Market Definition
1.3. Research Scope
1.3.1. Market Segmentation by Therapy
1.3.2. Market Segmentation by Product
1.3.3. Market Segmentation by Geography
1.3.4. Analysis Period
1.4. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By region
2.2.1.2. By industry participants
2.2.1.3. By company type
2.3. Market Size Estimation
2.4. Market Breakdown and Data Triangulation
2.5. Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1. Market Segmentation
4.1.1. Overview by Therapy
4.1.1.1. Nicotine replacement therapy(NRT)
4.1.1.1.1. NicoDerm CQ
4.1.1.1.2. Nicotrol
4.1.1.1.3. Habitrol(Nicotinell)
4.1.1.1.4. Nicorette
4.1.1.1.5. Niquitin
4.1.1.2. Non-NRT therapy
4.1.1.2.1. Prescription drug
4.1.1.2.1.1. Chantix
4.1.1.2.1.2. Zyban/Wellbutrin
4.1.1.2.2. E-cigarette
4.1.2. Overview by Product Type
4.1.2.1. Chewing gum
4.1.2.2. Patch
4.1.2.3. Lozenge
4.1.2.4. Sublingual tablets
4.1.2.5. Spray
4.1.2.6. Inhaler
4.2. Value Chain Analysis
4.3. Market Dynamics
4.3.1. Trends
4.3.2. Drivers
4.3.2.1. Impact analysis of drivers on market forecast
4.3.3. Restraints
4.3.3.1. Impact analysis of restraints on market forecast
4.3.4. Opportunities
4.4. Porter’s Five Forces Analysis
Chapter 5. Market Size and Forecast by Therapy
5.1. Nicotine Replacement Therapy(NRT)
5.1.1. NicoDerm CQ
5.1.2. Nicotrol
5.1.3. Habitrol(Nicotinell)
5.1.4. Nicorette
5.1.5. Niquitin
5.2. Non-NRT Therapy
5.2.1. Prescription drug
5.2.1.1. Chantix
5.2.1.2. Zyban/Wellbutrin
5.2.2. E-cigarette/E-liquids
Chapter 6. Market Size and Forecast by Product Type
6.1.1. Chewing gum
6.1.2. Patch
6.1.3. Lozenges
6.1.4. Sublingual Tablets
6.1.5. Spray
6.1.6. Inhaler
Chapter 7. Market Size and Forecast by Geography
7.1. North America Smoking Cessation Market
7.1.1. By Therapy
7.1.2. By Product Type
7.1.3. By Country-The U.S, Canada and Others
7.2. Europe Smoking Cessation Market
7.2.1. By Therapy
7.2.2. By Product Type
7.2.3. By Country –Germany, France, U.K and others
7.3. Latin America Smoking Cessation Market
7.3.1. By Therapy
7.3.2. By Product Type
7.3.3. By Country –Brazil and Mexico
7.4. Asia-Pacific Smoking Cessation Market
7.4.1. By Therapy
7.4.2. By Product Type
7.4.3. By Country -China, Japan, India and others
7.5. Middle East and Africa Smoking Cessation Market
7.5.1. By Therapy
7.5.2. By Product Type
7.5.3. By Country
Chapter 8. Competitive Landscape
8.1. Market Share Analysis of Major Players
8.2. Competitive Analysis of Key Players
8.3. Global Strategic Developments
Chapter 9. Company Profiles
9.1. Pfizer
9.1.1. Business Overview
9.1.2. Product and Service Offerings
9.1.3. Key Financial Summary
9.1.4. Strategic Growth Plan
9.2. GlaxoSmithKline (GSK)
9.2.1. Business Overview
9.2.2. Product and Service Offerings
9.2.3. Key Financial Summary
9.2.4. Strategic Growth Plan
9.3. Novartis
9.3.1. Business Overview
9.3.2. Product and Service Offerings
9.3.3. Key Financial Summary
9.3.4. Strategic Growth Plan
9.4. Johnson & Johnson (J&J)
9.4.1. Business Overview
9.4.2. Product and Service Offerings
9.4.3. Key Financial Summary
9.4.4. Strategic Growth Plan
9.5. Perrigo
9.5.1. Business Overview
9.5.2. Product and Service Offerings
9.5.3. Key Financial Summary
9.5.4. Strategic Growth Plan
9.6. Reynolds American Inc.
9.6.1. Business Overview
9.6.2. Product and Service Offerings
9.6.3. Key Financial Summary
9.6.4. Strategic Growth Plan
9.7. VMR Products LLC
9.7.1. Business Overview
9.7.2. Product and Service Offerings
9.7.3. Key Financial Summary
9.7.4. Strategic Growth Plan
9.8. British American Tobacco PLC
9.8.1. Business Overview
9.8.2. Product and Service Offerings
9.8.3. Key Financial Summary
9.8.4. Strategic Growth Plan
9.9. Nicotek LLC
9.9.1. Business Overview
9.9.2. Product and Service Offerings
9.9.3. Key Financial Summary
9.9.4. Strategic Growth Plan
9.10. Njoy Inc.
9.10.1. Business Overview
9.10.2. Product and Service Offerings
9.10.3. Key Financial Summary
9.10.4. Strategic Growth Plan
*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.
Chapter 10. Appendix
10.1. Abbreviations
